Biogen

Jul 26, 05 NEW STORY 16:04 ET Biogen Idec Reports Second Quarter 2005 Results      Apr 27, 05 16:03 ET Biogen Idec Reports First Quarter 2005 Results      Feb 07, 05 16:01 ET Biogen Idec Reports Fourth Quarter and Full Year 2004 Results      Nov 11, 04 17:24 ET The National MS Society, Biogen Idec, and MSWorld, Inc., Recognize Winners of the First Annual MS Leaders of Hope(SM)      Oct 28, 04 14:38 ET Biogen Idec Opens New San Diego Campus Featuring Community Lab for Local Students      Oct 27, 04 16:09 ET Biogen Idec Reports Third Quarter 2004 Results      Oct 13, 04 07:30 ET AMEVIVE(R) (alefacept) Approved in Canada      Aug 17, 04 16:01 ET Biogen Idec and Elan Announce Update on Global Filings and Data Release for ANTEGREN(R) for Multiple Sclerosis      Jul 29, 04 09:03 ET Biogen Idec Announces Additions to Leadership Team      Jul 28, 04 07:20 ET Biogen Idec Reports Second Quarter 2004 Results      Jul 19, 04 08:35 ET MS Leaders of Hope(SM) Honors the Creative Spirit in People With MS and Their Caregivers      Jul 07, 04 01:15 ET Biogen Idec Establishes New International Headquarters      Jun 17, 04 08:30 ET AMEVIVE(R) (alefacept) Approved in Australia   May 12, 04 17:05 ET Biogen Idec Announces Management Change      May 03, 04 08:32 ET AMEVIVE(R) (alefacept) Approved in Israel, Receives 'Positive Opinion' From Swiss Regulatory Authority      Apr 30, 04 07:03 ET Biogen Idec Reports First Quarter 2004 Earnings per Share of $0.40 (Adjusted Non-GAAP); - - - On a GAAP Basis, First Quarter Loss per Share of $0.12 Primarily Due to Merger-Related Accounting Impacts - - - First Quarter Revenues Up 24% (vs. Prior Year Pro      Apr 29, 04 08:06 ET Patients Show Improvement in Phase II Psoriasis Study of Novel Oral Immunomodulator      Mar 02, 04 18:24 ET Biogen Idec Reports Fourth Quarter Earnings per Share of $0.24 (Adjusted Pro Forma); Full Year 2003 Earnings per Share of $1.22 (Adjusted Pro Forma)      Feb 11, 04 17:31 ET Biogen Idec Reports 19 Percent Revenue Growth for 2003 (Unaudited Pro Forma Combined) - - - 2003 Full Year Revenues Exceed $1.85 Billion (Unaudited Pro Forma Combined) - - - 2003 Full Year Earnings to be Reported on March 2 - - -      Jan 22, 04 08:32 ET European Commission Approves Zevalin(R) (Ibritumomab tiuxetan) Radioimmunotherapy      Dec 05, 03 10:02 ET Biogen Idec Announces Webcast of Analyst Discussion at ASH      Nov 11, 03 18:30 ET Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference      Nov 10, 03 10:20 ET Biogen Announces Results of Phase II Trials With ADENTRI(TM) at American Heart Association Meeting      Oct 28, 03 07:33 ET Total Revenues Up 19 Percent Year-Over-Year      Oct 01, 03 08:22 ET Biogen Licenses Oral Psoriasis Therapy From Fumapharm AG      Sep 22, 03 08:04 ET New Study Shows Long-Term Effect of AVONEX(R) on MS      Aug 01, 03 11:14 ET FDA Approves Biogen's Large-Scale Manufacturing Facility for Commercial Production   Jul 24, 03 07:41 ET Biogen's Second Quarter 2003 Reported EPS Increased 31 Percent to $0.38; Second Quarter Operating EPS Increased 26 Percent to $0.39 over Second Quarter 2002      Jun 23, 03 11:30 ET Biogen & IDEC Announce Webcast of Today's (June 23) Investor Luncheon      Jun 20, 03 12:34 ET New Data on IM Administration Shows AMEVIVE(R) (alefacept) Provides Relief From Psoriasis For a Median of 7 Months      Jun 17, 03 08:13 ET Genentech and Biogen Announce Autoimmune Collaboration      Jun 13, 03 08:30 ET Biogen Obtains Rights To Genentech Immunoadheson Patents      Jun 06, 03 11:02 ET Biogen Annual Meeting Highlights      07:31 ET Biogen Concludes Its Participation in LFA-1 Antagonist Drug Development Program      Jun 04, 03 09:21 ET Biogen Announces Webcast of Presentation at the Goldman Sachs Global Healthcare Conference      May 30, 03 10:06 ET Data On Patients Treated With AVONEX(R) For Up To Eight Years Presented at Consortium of Multiple Sclerosis Centers' Annual Meeting      May 29, 03 08:25 ET FDA Approves Prefilled Syringe for AVONEX(R)      Apr 17, 03 07:29 ET Biogen Announces First Quarter 2003 Results      Apr 02, 03 09:01 ET Biogen Announces Improved Performance Expectations for First Quarter and Full Year 2003 - - - First Quarter 2003 Guidance Increased Based on Robust Revenues and Operational Efficiencies - - - Full Year Operating 2003 Guidance Increased to $1.72 - $1.85 -      Mar 27, 03 07:01 ET Biogen Breaks Ground on Large-Scale Manufacturing Facility in Denmark      Feb 20, 03 08:13 ET European Approval of AMEVIVE(R) Delayed      Feb 14, 03 08:23 ET Biogen Reports Updated Fourth Quarter and Full Year 2002 Results For Berlex Settlement      Feb 11, 03 08:44 ET Biogen Elects Boston Scientific CFO to its Board Of Directors      Feb 07, 03 07:39 ET AVONEX(R) Approved By FDA for Patients with Early Multiple Sclerosis      Feb 03, 03 07:27 ET U.S. Court of Appeals Issues Ruling on 'McCormick' Patents Litigation      Jan 31, 03 10:43 ET FDA Approves Biogen's AMEVIVE(R) (alefacept) for Treatment of Psoriasis      Jan 28, 03 08:18 ET Biogen Announces Fourth Quarter and Full Year 2002 Results      Jan 16, 03 11:39 ET Biogen Names Craig Eric Schneier, Ph.D. as Executive Vice President, Human Resources      Jan 07, 03 19:30 ET Biogen's CEO Profiles Long Term Earnings Growth Potential of 20 Percent      Dec 19, 02 16:31 ET Biogen Appoints Bob Hamm Senior Vice President of North American Commercial Operations      Dec 17, 02 10:07 ET Biogen Scientists Advance Understanding of Inflammatory Bowel Disease With New Discoveries and Identify Potential Novel Therapeutic Approaches      Dec 16, 02 11:08 ET Biogen Names Whaijen Soo, M.D., Ph.D. as Senior Vice President, Medical Research      Nov 26, 02 12:49 ET Neurology Study Finds Approved Dose of AVONEX(R) (Interferon Beta-1a) Equally Effective as Higher Dose in Treating Relapsing Multiple Sclerosis      Nov 22, 02 08:48 ET Early Results Suggest Alefacept Plus Light Therapy May Clear Psoriasis      Nov 14, 02 08:03 ET FDA Approves Labeling Change for Biogen's Avonex(R) (Interferon Beta-1a) to Indicate Lower Occurrence of Neutralizing Antibodies      Oct 18, 02 07:01 ET Biogen and Schering-Plough Settle Royalty Payment Arbitration      07:00 ET Biogen Announces Third Quarter 2002 Earnings      Sep 12, 02 18:00 ET Biogen's AMEVIVE(R) (Alefacept) Application on Track for Early 2003 Approval      Aug 26, 02 10:44 ET Biogen Statement on The Wall Street Journal Generic Drug Story      Aug 22, 02 13:09 ET Biogen Opens Community Laboratory, State-Of-The-Art Teaching Facility      Jul 30, 02 07:36 ET Biogen Announces Results From CDP 571 Studies In Crohn's Disease      Jul 29, 02 14:48 ET Biogen Scientists Part of Team That Advances Understanding of Angiogenesis and Inflammation      Jul 25, 02 12:11 ET Biogen Unveils Enhanced Multiple Sclerosis Web Site      Jul 18, 02 07:09 ET Biogen Announces Second Quarter 2002 Earnings Per Share of $0.29      Jul 16, 02 17:22 ET Jim Vincent Retires and Jim Mullen Elected Chairman of the Board of Directors Of Biogen      Jul 09, 02 10:06 ET Biogen Names Christine Carberry as Vice President, Program And Alliance Management      Jun 21, 02 11:46 ET Biogen Announces Webcast of Presentation at the 22nd Annual William Blair & Company Growth Stock Conference      Jun 13, 02 16:02 ET Biogen Receives "Complete Response" Letter from FDA on AMEVIVE(R) (alefacept) Application      Jun 10, 02 13:36 ET Biogen Invites Public to Listen to Webcast of Annual Stockholders Meeting Friday, June 14, 2002 at 10:00 AM (EDT)      Jun 07, 02 07:02 ET Biogen Announces Revised 2002 Financial Guidance      Jun 06, 02 16:10 ET Biogen to Provide Mid-Quarter Financial Update      May 23, 02 17:43 ET FDA Advisory Committee Recommends Approval of Biogen's AMEVIVE(R)      May 21, 02 10:11 ET Biogen Names Nicolas Barthelemy as Vice President, Manufacturing and General Manager, Research Triangle Park, North Carolina      May 20, 02 10:41 ET Biogen's AVONEX(R) (Interferon beta-1a) Approved in Europe for Treatment of Patients at High Risk for Developing Multiple Sclerosis      09:48 ET Biogen Announces $25,000 Annual Commitment to Crown Prince Frederik Fund      May 16, 02 09:54 ET AVONEX(R) (Interferon beta-1a) Gains Medicare Coverage      May 10, 02 10:46 ET Biogen Names Michael Kowolenko, Ph.D. as Vice President, Global Quality      May 08, 02 11:22 ET Biogen Dedicates Two New World-Class Facilities in Research Triangle Park, North Carolina      May 06, 02 10:28 ET Biogen Revamps Multiple Sclerosis Web Site      May 01, 02 09:53 ET Biogen Launches PsoriasisSupport.com      Apr 24, 02 07:09 ET Biogen Announces First Quarter 2002 Earnings Per Share of $0.47      Apr 18, 02 17:01 ET New Long-Term Data on AVONEX(R) (Interferon beta-1a) Presented at Annual Meeting of Neurologists      Apr 16, 02 11:34 ET Biogen Launches First Long-Term Study Comparing AVONEX(R) (Interferon beta-1a) and REBIF(R) In Treatment of Multiple Sclerosis      Apr 08, 02 09:33 ET Biogen Named Project Excellence Award Winner      Apr 02, 02 09:40 ET Biogen Names John Palmer as Senior Vice President, Corporate Development      Apr 01, 02 09:29 ET Biogen Announces Meeting of FDA Advisory Committee to Review AMEVIVE(R) (Alefacept) For Treatment of Psoriasis      Mar 26, 02 10:14 ET Biogen and MIT Establish Toxicology Fellowship Program      Mar 25, 02 10:56 ET Eckhard Pfeiffer Elected to Biogen Board of Directors      Mar 12, 02 10:27 ET FDA Says No Clinical Superiority in Labeling for Rebif(R)      Feb 22, 02 10:37 ET Biogen to Present at the Lehman Brothers' Global Health Care Conference February 26, 2002      Jan 24, 02 08:26 ET Biogen Settles Patent Litigation With Berlex Laboratories      08:20 ET Biogen Delivers on Operating Earnings Guidance of $1.90 Per Share After One- Time Charges      Jan 07, 02 16:33 ET Biogen, Inc. to Provide Company Update at JP Morgan H&Q Healthcare Conference in San Francisco      Dec 21, 01 15:31 ET Biogen Says 2001 Revenues Will Exceed $1 Billion      Nov 02, 01 17:40 ET Biogen Announces New Appointments in its International Operation      Nov 01, 01 15:25 ET Biogen Cites Goal of Surpassing $2 Billion in Revenues in 2005      Oct 29, 01 17:53 ET $1 Million 'Biogen Legacy Fund' Established, Donated To 'Families Of Freedom Scholarship Fund(TM)"      Oct 25, 01 13:57 ET Biogen Appoints Peter N. Kellogg Executive Vice President, Finance and Chief Financial Officer      13:56 ET Biogen Appoints Frank A. Burke, Jr. Executive Vice President, Human Resources      13:55 ET Biogen Appoints Thomas Bucknum, Esq. Executive Vice President & General Counsel      Oct 16, 01 08:07 ET Biogen Announces Third Quarter 2001 Earnings Per Share Increased to $0.46 From $0.44 in 2000      Oct 10, 01 10:09 ET Biogen Schedules Third Quarter 2001 Financial Results for October 16, 2001      Oct 05, 01 10:10 ET Biogen Says Regulatory Agencies in U.S. and Europe Have Officially Accepted Filings for Amevive(R) (Alefacept) for Treatment of Psoriasis      Oct 01, 01 16:07 ET Biogen Appoints Burt Adelman, M.D. Executive Vice President, Research And Development      Sep 06, 01 14:40 ET Biogen Scientists Identify Presence of Key Genes in Kidney Fibrosis, Pointing To Possible New Therapeutic Approaches      Aug 27, 01 14:17 ET Biogen Appoints Sylvie Gregoire, Pharm. D., Executive Vice President, Technical Operations      Aug 18, 01 07:18 ET Swiss Court Rules In Favor of Biogen, Upholds Injunction Against Serono      Aug 16, 01 14:01 ET Biogen Research Reported in 'Science' Signals Important New Target for Drug Development to Treat Lupus, Other Autoimmune Disorders      Aug 06, 01 15:26 ET Biogen Completes International Registrational Filing For AMEVIVE(TM) (ALEFACEPT)      Aug 01, 01 16:02 ET Biogen Appoints Hans-Peter Hasler Executive Vice President, Commercial Operations      09:02 ET Biogen Files For Arbitration Against Schering-Plough      Jul 17, 01 07:47 ET Biogen Reports Second Quarter 2001 Results      Jul 16, 01 07:45 ET ICOS and Biogen Collaborate to Develop Oral Therapeutics for Autoimmune and Inflammatory Diseases      Jul 10, 01 13:47 ET Biogen Schedules Second Quarter 2001 Financial Results for July 17, 2001   Jun 22, 01 10:52 ET Serono's Marketing Study Misleading to Doctors and People with MS; Lacks Scientific Rigor, Biogen Says      Jun 19, 01 11:16 ET Biogen to Webcast the June 22 Discussion of Amevive Phase III Results      Jun 12, 01 15:05 ET Biogen, Inc. to Webcast Annual Meeting of Shareholders on June 15, 2001 at 10:00 AM      May 15, 01 05:30 ET Biogen Selects Denmark's 'Medicon Valley' as Site for its First International Major Manufacturing Facility      May 08, 01 19:14 ET Biogen Says Serono Six-Month Data Not Meaningful When Deciding on Long-Term Treatment Of Multiple Sclerosis      Apr 19, 01 10:17 ET Biogen Appoints David M. Buckley Executive Vice President, Technical Operations      Apr 12, 01 07:24 ET Biogen Reports Record Results for First Quarter 2001      Apr 04, 01 17:06 ET Biogen Schedules First Quarter 2001 Financial Results for April 12, 2001      Mar 27, 01 16:15 ET Biogen Reaffirms First Quarter and Full Year 2001 Guidance With Update on Royalty Revenue Status      Mar 26, 01 11:09 ET Biogen Launches MSActiveSource.com      Mar 19, 01 16:01 ET Positive Results With Biogen's A1 Adenosine Receptor Antagonist in Congestive Heart Failure Presented at American College of Cardiology      Mar 05, 01 09:03 ET AMEVIVE(TM) Phase II Clinical Trial on Retreatment of Patients With Moderate to Severe Chronic Plaque Psoriasis Presented at American Academy of Dermatology      Feb 22, 01 10:40 ET Biogen Appoints Dr. Toshio Nakata President, Biogen Japan Ltd. and Vice President, Biogen Inc.      Feb 02, 01 12:01 ET Biogen Names Patrick J. Purcell Vice President, Chief Information Officer      Jan 22, 01 16:46 ET Elan and Biogen Announce Positive Phase II Results for Antegren(R) (Natalizumab) in Multiple Sclerosis and Crohn's Disease      Jan 17, 01 16:25 ET Biogen Reports Fourth Quarter and 2000 Results      Jan 16, 01 13:44 ET New Study with Biogen's AVONEX(R) (Interferon Beta-1a) in Secondary Progressive Multiple Sclerosis Achieves Primary Endpoint      Jan 12, 01 18:45 ET Webcast to Discuss Biogen's Fourth Quarter and Year End 2000 Earnings      Jan 09, 01 12:30 ET Biogen Says it Expects Number of Drugs in Clinical Pipeline to Double in 2001      Jan 08, 01 16:15 ET Biogen, Inc. to Provide Company Update at Chase H&Q Healthcare Conference in San Francisco      Dec 18, 00 17:00 ET Biogen Scientists Demonstrate On A Genome-Wide Basis That The Extracellular Matrix Regulates Gene Expression      13:00 ET Biogen Announces That Board of Directors Authorizes Repurchase of up to 4,000,000 Shares of Common Stock      Dec 06, 00 09:02 ET Biogen Executes License Agreement With NsGene A/S For Novel Neurotrophic Protein      Oct 24, 00 12:20 ET Early Recognition of Symptoms by Ophthalmologists Could Help Delay the Onset Of Multiple Sclerosis in High-Risk Patients      Oct 17, 00 16:53 ET AVONEX(R) (Interferon beta-1a) Shown to be Most Potent Inhibitor of Key Multiple Sclerosis Antibody      Oct 12, 00 04:00 ET Biogen Appoints Professor Cornelis Lucas As Director, International Science And Technology Development      Oct 10, 00 17:08 ET Biogen Reports Third Quarter 2000 Results      Oct 06, 00 16:46 ET Biogen Announces Realignment of Management Positions      Sep 20, 00 17:20 ET Biogen Says That Judge Enters Final Judgment on All Claims in Berlex Lawsuit      Sep 13, 00 01:01 ET Biogen and Eos Biotechnology Announce Genomic Target & Therapeutic Antibody Collaboration      Aug 17, 00 07:32 ET Biogen and Elan to Collaborate on Development and Commercialization Of Antegren(R) (natalizumab)      Aug 15, 00 18:05 ET Biogen Praises Court Ruling That AVONEX(R) Does Not Infringe Berlex 'McCormick' Patents      Aug 09, 00 07:45 ET Biogen and Targeted Genetics to Collaborate on Gene Therapy Research      Jul 11, 00 16:06 ET Biogen Reports Second Quarter 2000 Results      Jul 10, 00 09:59 ET Biogen Appoints Peter N. Kellogg Vice President, Finance and Chief Financial Officer      Jun 28, 00 09:01 ET Biogen Dedicates Its First European Manufacturing Facility, a Commercial Packaging Center in The Netherlands      Jun 20, 00 11:30 ET Biogen Expands in Research Triangle Park, North Carolina, With New Large-Scale Manufacturing Facility      Jun 16, 00 14:52 ET James C. Mullen Becomes Biogen's Chief Executive Officer at Annual Shareholder Meeting      May 09, 00 14:12 ET Biogen Appoints John W. Palmer as Vice President-Program Management, a New Position      May 02, 00 16:03 ET James C. Mullen Named Chief Executive Officer of Biogen      09:14 ET Biogen Presents Data From Its CHAMPS Trial at the American Academy of Neurology Annual Meeting      Apr 10, 00 17:38 ET Biogen Reports First Quarter 2000 Results      16:36 ET Biogen Appoints Michael Gilman, Ph.D. to Position of Vice President-Research      Apr 05, 00 09:59 ET Biogen Introduces MS ActiveSource(SM)      Mar 22, 00 16:01 ET Arbitration Ruling Denies Biogen's Claims Against Schering-Plough on Sales of REBETRON      Feb 24, 00 10:24 ET Biogen Names John McCoy, Ph.D., Director, Molecular Technologies      10:22 ET Biogen Announces New Executive Assignments in Its International Operations      10:20 ET Biogen Names Raymond G. Arner Chief Counsel, Intellectual Property      10:19 ET Biogen Names Nadine Cohen, Ph.D., Director of Regulatory Affairs      Feb 17, 00 17:53 ET Biogen and CV Therapeutics Say Adenosine A1 Antagonist Is Successful in a Phase II Trial      16:22 ET Biogen Announces Resignation of Timothy M. Kish, Vice President-Finance And Chief Financial Officer      Feb 01, 00 12:00 ET Biogen's AVONEX(R) (Interferon beta-1a) Shows A Beneficial Effect On Delaying The Development Of Multiple Sclerosis      Jan 13, 00 16:15 ET Biogen Reports Record Fourth Quarter and 1999 Results      Jan 11, 00 14:29 ET Biogen to Announce AVONEX(R) Fourth Quarter 1999 Sales Of About $180 Million and EPS of Approximately $0.44      Dec 03, 99 11:43 ET Investigators Present Positive Results of Phase II Study of AMEVIVE(TM) (Recombinantly Engineered LFA-3/IgG1 Human Fusion Protein) At a Meeting in London      Nov 05, 99 15:00 ET Biogen Names Andrew Komjathy as Country Manager-Canada      Nov 02, 99 20:00 ET Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody      16:05 ET Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody      Oct 21, 99 16:34 ET Biogen Says It Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody      Oct 07, 99 16:06 ET Biogen Reports Third Quarter 1999 Results AVONEX(R) Prescription Growth Drives Earnings Increase      Oct 04, 99 12:58 ET Biogen Breaks Ground for New R&D Center in Cambridge      12:21 ET Biogen Establishes Nordic Operations      Sep 15, 99 16:01 ET Biogen Says It Expects Greater Growth and Higher Earnings in Third Quarter      Aug 27, 99 13:04 ET Biogen Appoints Kees Been Vice President, Business & Market Development      Jul 08, 99 16:05 ET Biogen Reports Second Quarter 1999 Results Record Revenues and Number of AVONEX(R) Patients Reported   Jun 28, 99 16:01 ET Biogen Appoints Robert Hamm as Vice President, Manufacturing, Replacing David C. Dlesk   Jun 23, 99 09:19 ET Biogen Receives Clearance to Build New R&D Facility in Cambridge   Jun 17, 99 14:45 ET Biogen Appoints Thomas J. Bucknum as Vice President-General Counsel and Secretary, Replacing Michael J. Astrue   Jun 11, 99 13:40 ET Biogen Announces 2-for-1 Stock Split   May 25, 99 16:01 ET Biogen Announces That AMEVIVE(TM) Shows Excellent Dose Response With Positive Side-Effect Profile in Phase II Psoriasis Study   May 17, 99 16:01 ET Biogen Names Jennifer Jackson, Ph.D., as Director, Regulatory Affairs   16:00 ET Biogen Names Michael Gilman, Ph.D., as Research Director of Molecular Biology   Apr 29, 99 16:15 ET Biogen Announces Series of Corporate Donations to Cambridge Organizations   Apr 27, 99 14:28 ET President Clinton Presents National Medal of Technology to Biogen Chairman and CEO at White House Ceremony   Apr 16, 99 09:27 ET Biogen Announces 2-For-1 Stock Split And New Shareholder Rights Plan   09:27 ET James C. Mullen Elected to Biogen Board of Directors   Apr 08, 99 16:29 ET Biogen Reports Record First Quarter 1999 Results   Mar 24, 99 13:00 ET Biogen Names David Foster Director of Government Relations   Mar 01, 99 18:35 ET Biogen Commends FDA Ruling Upholding Orphan Drug Act With Regard to AVONEX(R) (Interferon Beta-1a)   Feb 23, 99 13:00 ET Biogen and Ontogeny Extend Hedgehog Protein Research Collaboration   Feb 22, 99 16:18 ET Biogen Announces That Board of Directors has Authorized Repurchase of Up to 4,000,000 Shares of Common Stock   Jan 14, 99 16:13 ET Biogen Reports Record Fourth Quarter and 1998 Results   Jan 12, 99 14:30 ET Biogen's AVONEX(R) (Interferon beta-1a) Ranks As World's Leading Treatment For Multiple Sclerosis   Jan 06, 99 13:21 ET Biogen Announces New Executive Assignments   13:20 ET Biogen Promotes James C. Mullen to President and Chief Operating Officer      Dec 29, 98 13:15 ET Biogen Announces Legal Settlements   Dec 23, 98 13:00 ET Biogen, Inc. Announces Election of James L. Vincent as CEO; Board Accepts Resignation of James R. Tobin   Dec 08, 98 15:34 ET Biogen Receives National Medal of Technology, Nation's Highest Honor For Innovation   Oct 19, 98 13:17 ET Biogen Commends National Multiple Sclerosis Society For Taking Strong Stance On Early Drug Treatment For People With MS   Oct 14, 98 11:57 ET Biogen Announces That It Has Opposed Rentschler's European Beta Interferon Patent   Oct 05, 98 16:08 ET Biogen Reports Third Quarter 1998 Results   Sep 24, 98 16:01 ET Biogen Announces that German Court Enjoins Schering A.G. From Issuing Inaccurate Information Relating to Avonex (Interferon Beta-1a) Dosing   Sep 23, 98 14:58 ET Biogen Names Michael A. Kelly as Corporate Controller   Aug 19, 98 08:29 ET Biogen Says That Berlex Suit Substitutes Courtroom For Marketplace   Jul 09, 98 16:18 ET Biogen Reports Second Quarter 1998 Results   Jun 18, 98 16:05 ET Biogen Announces New Agreements Related To Alpha Interferon Patents   May 19, 98 13:11 ET Biogen's AVONEX Awarded 1998 Prix Galien In France   May 18, 98 08:29 ET Asta Medica Files Suit Against Biogen   May 06, 98 16:38 ET Biogen Wins Class-Action Suit: Unanimous Decision Confirms Case Was Without Merit   16:38 ET Biogen Wins Class-Action Suit: Unanimous Decision Confirms Case Was Without Merit   Apr 08, 98 16:24 ET Biogen Reports First Quarter 1998 Results   Mar 16, 98 07:44 ET Arbitration Panel Denies ASTA Claim Against Biogen For Supply of Beta Interferon   Feb 03, 98 14:28 ET Biogen Appoints Larry Gatlin, Ph.D., as Director of Pharmaceutical and Analytical Development   Jan 15, 98 16:34 ET Biogen Reports Record Fourth Quarter and 1997 Results   Jan 13, 98 16:12 ET Biogen's AVONEX (Interferon Beta-1a) Maintains #1 Position in U.S. MS Market at End of First Full Year on the Market   Dec 15, 97 10:25 ET Former U.S. Senator Alan K. Simpson Elected to Biogen Board of Directors   Dec 03, 97 08:01 ET Biogen Announces Collaborative Agreement with Merck to Develop and Market a Novel Class of Compounds for Asthma and Other Anti-Inflammatory Indications   Oct 08, 97 16:29 ET Biogen Reports Third Quarter 1997 Results   Oct 06, 97 16:31 ET Biogen Announces That Board Of Directors Authorizes Repurchase Of Up To 2,500,000 Shares Of Common Stock   Sep 24, 97 16:27 ET Man Completing Mississippi River Swim for Multiple Sclerosis Nick Irons' Four Month, 1,550 Mile Journey to Help His Dad   Sep 16, 97 14:36 ET Biogen Appoints John Conley Treasurer and Director of Investor Relations   Jul 10, 97 16:16 ET Biogen Reports Second Quarter 1997 Results   Jun 06, 97 14:40 ET Dr. Mary L. Good, Former Under Secretary For Technology At U.S. Department Of Commerce, Elected To Biogen Board Of Directors   May 05, 97 12:21 ET Biogen Introduces the Avonex Alliance   Apr 23, 97 12:10 ET Biogen Announces That Rentschler's Beta Interferon Patent is Revoked by European Patent Office   Apr 10, 97 16:34 ET Biogen Reports First Quarter 1997 Results And Commencement Of New Clinical Trials   Apr 09, 97 11:12 ET Biogen Announces That Its Beta Interferon Patent Is Revoked By European Patent Office   Apr 03, 97 16:51 ET Biogen Appoints Torsten R. Goesch, M.D., as Country Manager, Germany   16:46 ET Biogen Appoints Wendy Gabel as Regional Sales Director, Northeast   Mar 25, 97 08:41 ET Biogen Licenses Rights to Hirulog to The Medicines Company   Mar 17, 97 07:33 ET Biogen Receives Approval To Market AVONEX (Interferon Beta-1a) For Treatment Of Relapsing Multiple Sclerosis In The European Union   Mar 10, 97 07:44 ET Biogen and CV Therapeutics Announce Collaboration on CVT-124 for Congestive Heart Failure   Mar 03, 97 12:48 ET Biogen and Genesis Pharma SA Sign Distribution Agreement for AVONEX (Interferon Beta-1a) in Greece   Feb 14, 97 13:32 ET James R. Tobin Named Chief Executive Officer of Biogen   Jan 28, 97 10:06 ET Biogen Announces Favorable Decision Affecting Lawsuit Related to European Hepatitis B Patent Extension   Jan 17, 97 15:09 ET Biogen Appoints Mary C. O'Connell As Director-Tax Affairs   15:06 ET Biogen Appoints James Green, Ph.D., As Director, Preclinical Development   Jan 14, 97 16:44 ET Biogen Reports Fourth Quarter and 1996 Results   Jan 07, 97 15:27 ET Biogen's Avonex Leads U.S. MS Market At End Of 1996 Record Sales And Net Income Expected For Year   Dec 10, 96 08:11 ET Biogen and Creative Biomolecules Sign Agreement to Develop Novel Drugs for Renal Disorders   Nov 21, 96 08:30 ET Biogen Announces Major Step Toward European Approval of Interferon Beta-1a   Oct 31, 96 15:02 ET Biogen Appoints Mark Leuchtenberger as Vice President, Marketing and Sales, Replacing Kenneth Bate   10:36 ET Biogen Announces That U.K. House Of Lords Rules That British Hepatitis B Patent Is Invalid   Oct 22, 96 10:52 ET Biogen Announces 2-For-1 Stock Split   Oct 17, 96 15:12 ET Biogen Announces Beginning of Phase I Clinical Trial of Gelsolin as Potential Treatment for Respiratory Diseases   Oct 09, 96 16:39 ET Biogen Reports Strong Sales Of AVONEX Record Revenues And Earnings In Third Quarter   Oct 08, 96 08:47 ET Biogen Announces Dismissal Of Berlex Suit   Sep 20, 96 14:28 ET Thomas F. Keller, Former Dean of Fuqua School of Business, Elected to Biogen Board of Directors   Aug 08, 96 14:45 ET Biogen Announces European Distribution Agreements For Interferon Beta-1a With Astra And Schering-Plough   Jul 30, 96 16:15 ET BIOGEN REPORTS SECOND QUARTER RESULTS   Jul 19, 96 10:41 ET BIOGEN AND ONTOGENY SIGN COLLABORATIVE AGREEMENT TO DEVELOP 'HEDGEHOG' PROTEINS